share_log

Transcode Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Transcode Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Transcode Therapeutics | PRE 14A:並購重組委托聲明
美股SEC公告 ·  10/15 17:25

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually in November 2024, with the exact date yet to be determined. The meeting will address three key proposals: the ratification of a securities issuance and sale agreement with ThinkEquity LLC, an amendment to the company's certificate of incorporation to effect a reverse stock split, and a proposal to adjourn the meeting if necessary to solicit additional votes. The reverse stock split aims to increase the market price of TransCode's common stock to comply with Nasdaq's minimum bid price requirement. The board has approved the reverse stock split, with the ratio to be determined by the board within a range of 1-for-10 to 1-for-40. The...Show More
TransCode Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually in November 2024, with the exact date yet to be determined. The meeting will address three key proposals: the ratification of a securities issuance and sale agreement with ThinkEquity LLC, an amendment to the company's certificate of incorporation to effect a reverse stock split, and a proposal to adjourn the meeting if necessary to solicit additional votes. The reverse stock split aims to increase the market price of TransCode's common stock to comply with Nasdaq's minimum bid price requirement. The board has approved the reverse stock split, with the ratio to be determined by the board within a range of 1-for-10 to 1-for-40. The ratification proposal seeks to address a compliance issue with Nasdaq Listing Rule 5635(d), which requires shareholder approval for certain transactions. The adjournment proposal would allow the meeting to be postponed to secure sufficient votes for the ratification or reverse stock split proposals if initially there are not enough votes. The board has recommended stockholders vote in favor of all three proposals. The preliminary proxy statement, dated October 15, 2024, is subject to completion, and the company has begun mailing proxy materials to stockholders as of October 2024.
TransCode Therapeutics, Inc.宣佈將於2024年11月虛擬舉行股東特別會議,確切日期尚未確定。會議將討論三項關鍵提議:與ThinkEquity LLC的證券發行和銷售協議的批准,對公司章程的修改以實施股票合併,以及必要時推遲會議以徵求額外投票的提案。股票合併旨在提高TransCode普通股的市場價格,以符合納斯達克的最低買盤價格要求。董事會已批准股票合併,比例由董事會確定在1∶10至1∶40的區間內。批准提議旨在解決與納斯達克規則5635(d)的合規問題,該規則要求股東對某些交易進行批准。推遲提議將允許會議延期,以確保足夠的投票來批准或實施股票合併提議,如果初始情況下沒有足夠的票數。董事會建議股東投票贊成這三項提議。預先代理聲明日期爲2024年10月15日,涉及內容尚未完成,公司已於2024年10月開始向股東寄送代理材料。
TransCode Therapeutics, Inc.宣佈將於2024年11月虛擬舉行股東特別會議,確切日期尚未確定。會議將討論三項關鍵提議:與ThinkEquity LLC的證券發行和銷售協議的批准,對公司章程的修改以實施股票合併,以及必要時推遲會議以徵求額外投票的提案。股票合併旨在提高TransCode普通股的市場價格,以符合納斯達克的最低買盤價格要求。董事會已批准股票合併,比例由董事會確定在1∶10至1∶40的區間內。批准提議旨在解決與納斯達克規則5635(d)的合規問題,該規則要求股東對某些交易進行批准。推遲提議將允許會議延期,以確保足夠的投票來批准或實施股票合併提議,如果初始情況下沒有足夠的票數。董事會建議股東投票贊成這三項提議。預先代理聲明日期爲2024年10月15日,涉及內容尚未完成,公司已於2024年10月開始向股東寄送代理材料。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息